What the research found
Researchers tracked 230 people with osteoporosis starting denosumab therapy, measuring their bone turnover markers (specifically a resorption marker and a formation marker) before treatment began. They grouped patients by baseline turnover status—high, intermediate, or low—then followed BMD changes over five years.
The pattern was consistent: patients with higher pretreatment bone turnover saw larger BMD gains at both the spine and hip. Those with low baseline turnover showed substantially smaller responses. At the hip specifically, the low-turnover group gained only about 2.5% BMD over five years versus 10.6% in the high-turnover group—a fourfold difference. Spine responses were less dramatic but followed the same gradient.
Why it matters for you
If you're considering denosumab (or already on it) and track bone biomarkers through MyKine, your baseline turnover status may predict how much your BMD will actually improve on treatment. This is relevant because BMD is your primary lever for fracture risk reduction on an antiresorptive drug—if your turnover is low to begin with, you might achieve less BMD gain, which could influence the decision to start denosumab versus alternatives, or affect realistic expectations for follow-up scans.
The finding doesn't change what denosumab does mechanically (it blocks resorption), but it suggests the drug works best in people whose bones are already remodeling more actively. If you have pre-existing low bone turnover—which can occur in some metabolic states, with certain medications, or simply by genetic predisposition—you might benefit from discussion with your clinician about whether combination strategies (e.g., adding an anabolic agent) or sequencing matter more than for higher-turnover patients.
Practically: request your TRACP-5b and P1NP values before starting denosumab if possible, calculate the turnover index described here, and use it as context for interpreting your 2–5 year BMD response rather than as a reason to avoid treatment.
Caveats
- Retrospective observational study (no randomization; causality not established)
- Population limited to patients with primary osteoporosis; generalizability to other bone conditions or prevention-only cohorts unclear
- Turnover index combines only two markers; other aspects of bone biology not captured
- No data on fracture outcomes—BMD gains in low-turnover patients may still reduce fracture risk meaningfully
- Long-term adherence and persistence data not reported; dropout bias possible